IN2014KN01714A - - Google Patents

Info

Publication number
IN2014KN01714A
IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01714A publication Critical patent/IN2014KN01714A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The present invention discloses an antibody that targets a cancer antigen protein expressed specifically on the surface of cancer cells and the application of the antibody in a treatment and/or preventative agent for said cancer. Specifically disclosed are: an antibody or a fragment thereof said antibody being immunologically reactive with a partial polypeptide of CAPRIN 1 comprising the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence represented by SEQ ID NO: 5; and a pharmaceutical composition for the treatment and/or prevention of cancer said pharmaceutical composition being characterized by containing as an active ingredient the antibody or a fragment thereof.
IN1714KON2014 2012-02-21 2013-02-21 IN2014KN01714A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035342 2012-02-21
PCT/JP2013/054312 WO2013125630A1 (en) 2012-02-21 2013-02-21 Pharmaceutical composition for treatment and/or prevention of cancer

Publications (1)

Publication Number Publication Date
IN2014KN01714A true IN2014KN01714A (en) 2015-10-23

Family

ID=49005808

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1714KON2014 IN2014KN01714A (en) 2012-02-21 2013-02-21

Country Status (17)

Country Link
US (1) US9260513B2 (en)
EP (1) EP2818481B1 (en)
JP (1) JP6187257B2 (en)
KR (1) KR102005308B1 (en)
CN (1) CN104114581B (en)
AU (1) AU2013223137B2 (en)
BR (1) BR112014021099A2 (en)
CA (1) CA2864999C (en)
DK (1) DK2818481T3 (en)
ES (1) ES2749672T3 (en)
HU (1) HUE046788T2 (en)
IN (1) IN2014KN01714A (en)
MX (1) MX363136B (en)
PL (1) PL2818481T3 (en)
PT (1) PT2818481T (en)
RU (1) RU2639522C2 (en)
WO (1) WO2013125630A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733223C (en) * 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
MX2011001445A (en) 2008-08-05 2011-04-05 Toray Industries Cancer detection method.
MX340015B (en) * 2010-02-04 2016-06-22 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
WO2013018885A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Method for detecting pancreatic cancer
EP2740489B1 (en) * 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
IN2014KN01715A (en) 2012-02-21 2015-10-23 Toray Industries
CA2869120C (en) * 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
PL2832366T3 (en) 2012-03-30 2018-04-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
JP6244912B2 (en) 2012-07-19 2017-12-13 東レ株式会社 Cancer detection method
RU2646466C2 (en) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Method for cancer detection
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR20230149857A (en) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
AU2017348734A1 (en) 2016-10-28 2019-05-16 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
BR112020019935A2 (en) 2018-03-30 2021-01-26 Toray Industries, Inc. medicine for the treatment and / or prevention of cancer, agents that increase the effectiveness of a drug and method of treatment and / or prevention of cancer
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020252294A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
MX2022004875A (en) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Thienoazepine immunoconjugates, and uses thereof.
JPWO2021182570A1 (en) 2020-03-12 2021-09-16
EP4119160A4 (en) * 2020-03-12 2024-04-03 Toray Industries Medicament for treatment and/or prevention of cancer
WO2021182573A1 (en) 2020-03-12 2021-09-16 東レ株式会社 Medicament for treatment and/or prevention of cancer
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2021182572A1 (en) 2020-03-12 2021-09-16
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
EP4196168A1 (en) 2020-08-13 2023-06-21 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
JPWO2022270523A1 (en) 2021-06-23 2022-12-29
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240042416A (en) 2021-07-27 2024-04-02 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
JPWO2023008461A1 (en) 2021-07-27 2023-02-02
KR20240041917A (en) 2021-07-27 2024-04-01 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3234604A1 (en) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
FR2761994B1 (en) 1997-04-11 1999-06-18 Centre Nat Rech Scient PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (en) 1998-07-14 2004-08-27 Корикса Корпорейшн Tumor polypeptide isolated from prostate and polynucleotide encoding thereof
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU4185100A (en) 1999-04-02 2000-10-23 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ES2295228T3 (en) 2000-11-30 2008-04-16 Medarex, Inc. TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES.
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (en) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100583331B1 (en) 2001-05-11 2006-05-26 기린 비루 가부시키가이샤 Artificial Human Chromosome Containing Human Antibody λ Light Chain Gene
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (en) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP1711525A2 (en) 2004-01-26 2006-10-18 Debiovision Inc. Neoplasm-specific polypeptides and their uses
MXPA06010715A (en) 2004-03-19 2007-05-23 Imclone Systems Inc Human anti-epidermal growth factor receptor antibody.
PE20060287A1 (en) 2004-03-30 2006-05-16 Glaxo Group Ltd HOSM SELECTIVE BINDING IMMUNOGLOBULINS
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN101141981A (en) 2005-01-21 2008-03-12 健泰科生物技术公司 Fixed dosing of her antibodies
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (en) 2008-03-14 2015-02-04 東ソー株式会社 Method for producing recombinant antibody
EP2644204B1 (en) 2008-03-18 2017-04-19 Genentech, Inc. Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
CA2733223C (en) * 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
PL2324842T3 (en) 2008-08-05 2015-08-31 Toray Industries Immunity-inducing agent
MX2011001445A (en) 2008-08-05 2011-04-05 Toray Industries Cancer detection method.
JP5734978B2 (en) 2009-08-19 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Antibodies for integrin complex detection in FFPE materials
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
RU2418587C1 (en) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Method of treating malignant brain tumours
KR101871704B1 (en) 2010-02-04 2018-06-27 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
RU2624029C2 (en) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Drugs for cancer treatment and/or prevention
HUE030742T2 (en) * 2010-02-04 2017-06-28 Toray Industries Pharmaceutical composition for treating and/or preventing cancer
MX340015B (en) 2010-02-04 2016-06-22 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
PT2532365T (en) 2010-02-04 2016-07-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
WO2012005550A2 (en) 2010-07-08 2012-01-12 강원대학교산학협력단 Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
ES2871092T3 (en) 2010-07-26 2021-10-28 Progastrine Et Cancers S A R L Methods and compositions for the therapy of liver cancer
JP5545105B2 (en) 2010-08-04 2014-07-09 株式会社ジェイテクト Disc polishing method for toroidal type continuously variable transmission and disk polishing apparatus for toroidal continuously variable transmission
WO2013018885A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Method for detecting pancreatic cancer
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PT2740796T (en) 2011-08-04 2017-07-26 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer
PL2832366T3 (en) 2012-03-30 2018-04-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer

Also Published As

Publication number Publication date
CN104114581B (en) 2018-11-30
CN104114581A (en) 2014-10-22
CA2864999C (en) 2020-06-30
US20150044221A1 (en) 2015-02-12
US9260513B2 (en) 2016-02-16
WO2013125630A1 (en) 2013-08-29
EP2818481A1 (en) 2014-12-31
EP2818481B1 (en) 2019-08-07
HUE046788T2 (en) 2020-03-30
PL2818481T3 (en) 2020-02-28
KR20140130670A (en) 2014-11-11
AU2013223137A1 (en) 2014-09-11
EP2818481A4 (en) 2015-10-07
MX2014009747A (en) 2014-11-14
BR112014021099A2 (en) 2020-12-01
PT2818481T (en) 2019-10-25
AU2013223137B2 (en) 2017-10-19
RU2639522C2 (en) 2017-12-21
KR102005308B1 (en) 2019-07-30
ES2749672T3 (en) 2020-03-23
MX363136B (en) 2019-03-12
JP6187257B2 (en) 2017-08-30
JPWO2013125630A1 (en) 2015-07-30
DK2818481T3 (en) 2019-10-14
CA2864999A1 (en) 2013-08-29
RU2014138039A (en) 2016-04-10

Similar Documents

Publication Publication Date Title
IN2014KN01713A (en)
IN2014KN01714A (en)
IN2014KN01716A (en)
IN2014KN01715A (en)
MX2014001375A (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer.
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
MX340014B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX342291B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX358224B (en) Pharmaceutical composition for treatment and/or prevention of liver cancer.
MX360671B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MX371442B (en) Fcyriib-specific fc region variant.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX357965B (en) Pharmaceutical composition for treatment and/or prevention of gall bladder cancer.
MY167232A (en) Polypeptides binding to human complement c5
AR120721A2 (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE
EA201790341A1 (en) ANTI-CK8 ANTIBODIES FOR USE IN TREATMENT OF CANCER
EA201590601A1 (en) APPLICATION OF PEDF-DERIVED POLYPEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS
IN2014DN09963A (en)
EP2552462A4 (en) Ccn3 peptides and analogs thereof for therapeutic use
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.
WO2014039074A3 (en) Therapeutic compositions and related methods